Clinical trial · Observational
Best Therapy for Patients With Neuroendocrine Tumors
NCT00815620CI-TRIAL-00026526BESTTHERAPYNETcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A prospective observational study containing three arms comprising different therapeutic measures to treat patients with neuroendocrine tumors in advanced stages. The therapy arms include local ablative therapy such as TACE or SIRT, surgery and RFA with peptide receptor radiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroendocrine Tumors | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- 1
- description
- patients undergoing local ablative therapy such as transcatheter-arterial chemoembolization or selective interal radiotherapy
- label
- 2
- description
- patients undergoing surgery or radiofrequency ablation
- label
- 3
- description
- patients undergoing peptide receptor radiotherapy
Primary outcomes (1)
- measure
- progression-free survival
- timeFrame
- 2 years
Secondary outcomes (1)
- measure
- overall survival, quality of life (EORTC-QLQ30), weight, time of hospitalization, Karnofsky index
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Biopsy-proven neuroendocrine tumor (WHO class I-II, TNM grading 1-2) * Advanced disease with lymph node or distant metastases (N1, M1) undergoing cytoreduction by surgery/local ablative therapy or peptide receptor radiotherapy * curative intent of all therapies possible Exclusion Criteria: * Undifferentiated neuroendocrine carcinoma (WHO class III, TNM grading 3) * secondary tumor * advanced carcinoid heart disease requiring surgery
References
Publications (0)
Data not yet available
No reference posted for this study.